# Vertex Pharmaceuticals Raises 2026 Revenue Guidance After Mixed Q3

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/47199
Published: 2026-11-03T02:59:10.000Z
Updated: 2026-11-03T02:59:10.000Z
Section: Business

> The new range tops out below the $13.28 billion consensus estimate, as quarterly revenue beat estimates and the bottom-line result missed.

Vertex Pharmaceuticals raised its 2026 revenue guidance to $13.15 billion to $13.25 billion, lifting both ends of its previous $13.1 billion to $13.2 billion range. The new high end remains below the $13.28 billion consensus estimate.

The updated outlook follows mixed third-quarter results: revenue exceeded estimates, while the bottom-line result fell short.